Casablanca

Researchers are studying the quality of primary healthcare for patients with arterial hypertension in Morocco, focusing on the diseases prevalence, types, complications, and treatment personalization. This observational cohort study aims to improve understanding and management of hypertension by comparing current data with past results and other North African countries. The study highlights key aspects like timely care, accessibility, and adherence to clinical guidelines. The study uses a remote electronic registry to collect anonymous medical data from both primary care and hospital settings. Trained investigators will standardize blood pressure measurements to reduce errors. Data gathered will include clinical details, treatments, complications, anthropometric measurements, blood pressure readings using validated devices or ambulatory monitoring, and metabolic assessments such as blood glucose and cholesterol levels. Cardiovascular complications will also be tracked. The follow-up period targets one year to observe complications related to hypertension. Participants aged 18 and older with diagnosed hypertension will provide informed consent before inclusion. Researchers will analyze the prevalence and geographic spread of hypertension, its various types, and associated complications at the study start. Data collection includes physical measurements, laboratory tests, and complication records. The study will compare findings to previous years and other countries to identify care gaps and progress. The total participation spans from initial inclusion through a one-year follow-up to monitor outcomes and inform better prevention and treatment strategies.

Researchers are evaluating DCR-PHXC in individuals with Primary Hyperoxaluria Type 1 PH1 who have severe kidney impairment, including those on dialysis. This Phase 2 open-label study aims to assess the safety and effectiveness of DCR-PHXC in this specific patient group, which includes adults, children, and infants under 6 years old. The study is conducted by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, and focuses on participants with a confirmed PH1 diagnosis and significant kidney function decline. Participants will receive monthly subcutaneous injections of DCR-PHXC, with dosing schedules adjusted according to age and weight. After a screening period of up to 35 days, monthly dosing visits will continue through Day 180. Those completing the initial treatment phase may enter an extended follow-up period of up to five years or until the drug becomes commercially available. During this extension, dosing may be administered at home by participants, caregivers, or home health nurses with training. Throughout the study, participants will attend regular clinic visits for dosing and assessment. Researchers will monitor safety by tracking incidence of adverse events over 180 days. They will also evaluate changes in plasma oxalate levels, dialysis frequency and duration, and pharmacokinetics of DCR-PHXC. The total study duration can extend up to 10 years including the extended follow-up phase. Participants health and treatment compliance will be regularly assessed to understand the long-term effects of DCR-PHXC.

Cardiovascular diseases are the leading cause of death worldwide and are increasing in prevalence in Morocco. Researchers are conducting a 10-year follow-up study of adults aged 40 and older who were screened for cardiovascular risk between 2010 and 2012 by the All with heart Association in the Greater Casablanca region. The study aims to evaluate long-term cardiovascular outcomes and develop a risk score specific to the Moroccan population to improve prevention and patient care. This observational study involves following participants who were part of the initial screening campaign, with no interventions applied. Data on cardiovascular events such as deaths, heart attacks, and strokes will be collected through phone calls, WhatsApp, or SMS with participants or their families. Statistical analyses will be used to identify key risk factors and create a predictive model tailored to Morocco. Participants will be contacted periodically to gather follow-up information on their cardiovascular health. The study will measure the incidence of major and minor cardiovascular events over ten years and work on validating a Morocco-specific cardiovascular risk score. The total participation duration is 10 years, with data collection relying on remote communication methods. Safety monitoring includes tracking cardiovascular-related outcomes and deaths.